# Denosumab and Osteoporotic Vertebral Compression Fracture

> **NCT05058443** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shenzhen People's Hospital** · enrollment: 90 (actual)

## Conditions studied

- Osteoporotic Vertebral Compression Fracture

## Interventions

- **DRUG:** Denosumab 60 mg/ml [Prolia]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05058443
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-06
- **Primary completion:** 2022-08-05
- **Final completion:** 2022-08-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05058443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05058443, "Denosumab and Osteoporotic Vertebral Compression Fracture". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05058443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*